Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 1;20(5):1075.
doi: 10.3390/ijms20051075.

Assessment of the Efficacy of Platelet-Rich Plasma in the Treatment of Traumatic Canine Fractures

Affiliations

Assessment of the Efficacy of Platelet-Rich Plasma in the Treatment of Traumatic Canine Fractures

Sergio López et al. Int J Mol Sci. .

Abstract

The role of platelet-rich plasma (PRP) in promoting the healing of bone fractures has not yet been clearly stated. The aim of this prospective clinical study was to evaluate the effectiveness of plasma rich in growth factors (PRGF, a PRP derivate) in the treatment of naturally-occurring bone fractures in dogs. With this objective, sixty-five dogs with radius/ulna or tibia/fibula bone fractures were randomly divided into two groups (PRGF and saline solution (SS) groups) and checked at days 0, 7, 14, 21, 28, 35, 42, 49, 56, 60, 63, 70, 120, and 180. All the fractures were treated with an external skeletal fixation, and pain was controlled with Carprofen. Healing was evaluated by physical examination, limb function, radiography, and by a Likert-type owner satisfaction questionnaire. A faster fracture healing was observed in the PRGF group, with statistically significant differences with respect to the SS group. Swelling at the fracture site was significantly greater at day 14 and 28 in animals injected with PRGF, and more pain on palpation was found in the area at day 28. The injection of PRGF in acute bone fractures accelerates bone healing.

Keywords: Carprofen; PRGF; bone healing; dog; fracture.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Boxplot corresponding to the days of implant removal for both PRGF and SS groups. Mean time was significantly higher in the SS group.

References

    1. Anitua E. The use of plasma-rich growth factors (PRGF) in oral surgery. Pract. Proc. Aesth. Dent. 2001;13:487–493. - PubMed
    1. Anitua E.A. Enhancement of osseointegration by generating a dynamic implant surface. J. Oral Implantol. 2006;32:72–76. doi: 10.1563/736.1. - DOI - PubMed
    1. Taschieri S., Rosano G., Weinstein T., Bortolin M., Del Fabbro M. Treatment of through-and-through bone lesion using autologous growth factors and xenogeneic bone graft: A case report. Oral Maxillofac. Surg. 2012;16:57–64. doi: 10.1007/s10006-010-0251-8. - DOI - PubMed
    1. Vilar J.M., Morales M., Santana A., Spinella G., Rubio M., Cuervo B., Cugat R., Carrillo J.M. Controlled, blinded force platform analysis of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells associated to PRGF-Endoret in osteoarthritic dogs. BMC Vet. Res. 2013;9:131. doi: 10.1186/1746-6148-9-131. - DOI - PMC - PubMed
    1. Jensen T.B., Bechtold J.E., Chen X., Vestermark M., Soballe K. No effect of autologous growth factors (AGF) around ungrafted loaded implants in dogs. Int. Orthop. 2010;34:925–930. doi: 10.1007/s00264-009-0897-8. - DOI - PMC - PubMed

Publication types

Substances